Anifrolumab (Saphnelo) March 6, 2024

March 6, 2024 – Lupus Canada is pleased to share that Saphnelo has been listed in Nova Scotia effective March 1, 2024.

The public notice and listing criteria will appear on the Nova Scotia Pharmacare Programs website when the March Bulletin is posted.

Lupus Blog Articles: Lupus lorem ipsum dolor sit amet est requiem deste natur.

The Lupus Canada Annual General Meeting 2026

Read

Disability Benefits in Canada | Pathway to Benefits

Read

Lupus Canada Impact Report 2025 | Advocacy, Awareness & Research Outcomes

Read